Suggest guests or get in contact

How do some countries consistently achieve lower HbA1c and better outcomes in type 1 diabetes while others struggle — even with the same technologies?

In this episode, John Pemberton speaks with Dr Peter Adolfsson, paediatric diabetologist in Sweden and lead author of the ISPAD 2022 Exercise Guidelines, about what actually drives population-level improvements in type 1 diabetes care.

Full show notes:

https://theglucoseneverlies.com/episode-34-building-high-performance-type-1-diabetes-care-technology-targets-and-equity-dr-peter-adolfsson/

KEY TOPICS

• How Sweden’s national diabetes registry drives accountability and rapid improvement
• Why structured onboarding and early follow-up are essential for CGM and AID success
• The role of national collaboration between clinics to share best practice
• Why the highest HbA1c group should often be first in line for AID systems
• Moving toward time in tight range (3.9–7.8 mmol/L) as the next clinical target
• Equity in diabetes technology: checking subconscious bias with real data
• Why celebrating small improvements builds long-term engagement

WHAT YOU’LL LEARN

✓ Why early investment in education and follow-up changes long-term outcomes
✓ How national benchmarking between clinics improves diabetes care
✓ Why targets matter — changing what you measure changes what improves
✓ How to use AID systems strategically for people struggling with bolusing
✓ Why the first two years after diagnosis are a critical window for glycaemic outcomes
✓ The importance of psychology, social support, and multidisciplinary teams

FUTURE OF TYPE 1 DIABETES CARE

• AI-supported platforms that analyse CGM data continuously
• Clinics responding earlier when glucose control deteriorates
• Personalised therapy combining insulin with adjunct treatments (e.g., GLP-1RA)
• More flexible care models where stable patients may need fewer clinic visits

Support GNL: https://buy.stripe.com/9B63cx4UO3KEdKC0Sp7Re00

The Glucose Never Lies® is a registered trademark of The GNL Ltd. Company No. 16733595. UK VAT No. GB 516 3272 08.

Disclaimer

This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.

The Glucose Never Lies® is independent by design

We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://www.buymeacoffee.com/jspfree2

Enquiries

Collaboration: John Pemberton — john@theglucoseneverlies.com

Creatives: Anjanee Kohli — anj@theglucoseneverlies.com

Follow The Glucose Never Lies®

Website: https://theglucoseneverlies.com/

Instagram: https://www.instagram.com/theglucoseneverlies

LinkedIn: https://www.linkedin.com/company/theglucoseneverlies

LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/

X: https://twitter.com/GlucoseNLies

Disclaimer
This content is for informational purposes only and does not constitute medical advice.

© The Glucose Never Lies Ltd. All rights reserved.